Multisystemic manifestations and genetic variants in SLC35A1-CDG: A synthesis of neurological and hematological phenotypes

https://doi.org/10.5281/zenodo.19672712

Authors

  • Sophya Amaral Neves Braga Centro Universitário Metropolitano da Amazônia (UNIFAMAZ)
  • Amanda Beatriz Pinheiro Macedo Centro Universitário Metropolitano da Amazônia (UNIFAMAZ)
  • Maria Eduarda de Lima Dacier Lobato Centro Universitário Metropolitano da Amazônia (UNIFAMAZ)
  • Jhon Lennon Ferreira Miranda Centro Universitário Metropolitano da Amazônia (UNIFAMAZ)
  • Carolyna Tereza Brasil Papaleo Centro Universitário Metropolitano da Amazônia (UNIFAMAZ)
  • Fernando Augusto Rezende Souza Centro Universitário do Estado do Pará (CESUPA)

Keywords:

transtornos congênitos da glicosilação, SLC35A1, sialilação, encefalopatia do desenvolvimento, macrotrombocitopenia

Abstract

SLC35A1-CDG is an ultrarare congenital disorder of glycosylation caused by biallelic variants in SLC35A1, which encodes the Golgi CMP-sialic acid transporter. This narrative review synthesizes the clinical and molecular spectrum of the disorder, with emphasis on neurological and hematological phenotypes. Available evidence shows that neurological impairment is constant, mainly presenting as developmental encephalopathy, intellectual disability, epilepsy, hypotonia, ataxia, and cerebellar abnormalities, whereas the hematological phenotype is variable, particularly macrothrombocytopenia and bleeding tendency. Clinical heterogeneity appears to result from distinct molecular mechanisms, including reduced transport activity, impaired protein stability, and altered interaction with sialyltransferases. SLC35A1-CDG should therefore be regarded as a multisystem sialylation disorder with still incomplete genotype-phenotype correlations and a major need for functional validation in diagnosis

References

FALKENSTEIN, Kristina et al. A novel missense variant in ultrarare SLC35A1-CDG alters cellular glycosylation, lipid, and energy metabolism without affecting CDG serum markers. Human Mutation, [s. l.], v. 2025, art. 6290620, 2025. Disponível em: https://doi.org/10.1155/humu/6290620. Acesso em: 10 jan. 2026.

KAUSKOT, Alexandre et al. A mutation in the gene coding for the sialic acid transporter SLC35A1 is required for platelet life span but not proplatelet formation. Haematologica, Pavia, v. 103, n. 12, p. e613-e617, 2018. Disponível em: https://doi.org/10.3324/haematol.2018.198028. Acesso em: 10 jan. 2026.

MA, Xiaolin et al. Slc35a1 deficiency causes thrombocytopenia due to impaired megakaryocytopoiesis and excessive platelet clearance in the liver. Haematologica, Pavia, v. 106, n. 3, p. 759-769, 2021. Disponível em: https://doi.org/10.3324/haematol.2019.225987. Acesso em: 10 jan. 2026.

MARTÍNEZ-DUNCKER, Ivan et al. Genetic complementation reveals a novel human congenital disorder of glycosylation of type II, due to inactivation of the Golgi CMP-sialic acid transporter. Blood, Washington, DC, v. 105, n. 7, p. 2671-2676, 2005. Disponível em: https://doi.org/10.1182/blood-2004-09-3509. Acesso em: 10 jan. 2026.

MASZCZAK-SENECZKO, Dorota et al. Delivery of nucleotide sugars to the mammalian Golgi: a very well (un)explained story. International Journal of Molecular Sciences, Basel, v. 23, n. 15, art. 8648, 2022. Disponível em: https://doi.org/10.3390/ijms23158648. Acesso em: 10 jan. 2026.

MOHAMED, Miski et al. Intellectual disability and bleeding diathesis due to deficient CMP-sialic acid transport. Neurology, Philadelphia, v. 81, n. 7, p. 681-687, 2013. Disponível em: https://doi.org/10.1212/WNL.0b013e3182a08f53. Acesso em: 10 jan. 2026.

NG, Bobby G. et al. Clinical and biochemical footprints of congenital disorders of glycosylation: proposed nosology. Molecular Genetics and Metabolism, San Diego, v. 142, n. 1, art. 108476, 2024. Disponível em: https://doi.org/10.1016/j.ymgme.2024.108476. Acesso em: 10 jan. 2026.

NG, Bobby G. et al. Encephalopathy caused by novel mutations in the CMP-sialic acid transporter, SLC35A1. American Journal of Medical Genetics Part A, Hoboken, v. 173, n. 11, p. 2906-2911, 2017. Disponível em: https://doi.org/10.1002/ajmg.a.38412. Acesso em: 10 jan. 2026.

QUELHAS, Dulce; JAEKEN, Jaak. Treatment of congenital disorders of glycosylation: an overview. Molecular Genetics and Metabolism, San Diego, v. 143, n. 1-2, art. 108567, 2024. Disponível em: https://doi.org/10.1016/j.ymgme.2024.108567. Acesso em: 10 jan. 2026.

RIEMERSMA, Moniek et al. Disease mutations in CMP-sialic acid transporter SLC35A1 result in abnormal α-dystroglycan O-mannosylation, independent from sialic acid. Human Molecular Genetics, Oxford, v. 24, n. 8, p. 2241-2246, 2015. Disponível em: https://doi.org/10.1093/hmg/ddu742. Acesso em: 10 jan. 2026.

SZULC, Bożena et al. Novel insights into selected disease-causing mutations within the SLC35A1 gene encoding the CMP-sialic acid transporter. International Journal of Molecular Sciences, Basel, v. 22, n. 1, art. 304, 2021. Disponível em: https://doi.org/10.3390/ijms22010304. Acesso em: 10 jan. 2026.

WIERTELAK, Wojciech; OLCZAK, Mariusz; MASZCZAK-SENECZKO, Dorota. An interaction between SLC35A1 and ST3Gal4 is differentially affected by CDG-causing mutations in the SLC35A1 gene. Biochemical and Biophysical Research Communications, New York, v. 635, p. 46-51, 2022. Disponível em: https://doi.org/10.1016/j.bbrc.2022.10.019. Acesso em: 10 jan. 2026.

Published

2026-04-21

How to Cite

Braga, S. A. N., Macedo, A. B. P., Lobato, M. E. de L. D., Miranda, J. L. F., Papaleo, C. T. B., & Souza, F. A. R. (2026). Multisystemic manifestations and genetic variants in SLC35A1-CDG: A synthesis of neurological and hematological phenotypes: https://doi.org/10.5281/zenodo.19672712. Journal of Convergent Scientific Inquiry, 2(4), 31–35. Retrieved from https://jcsi.ufrdj.com/index.php/jcsi/article/view/27

Issue

Section

Revisão Narrativa ou Integrativa

Most read articles by the same author(s)